SCHEMBL23217708

SCHEMBL23217708

CCOC(=O)Cc1ccccc1OC(C(=O)OCC)c1cc(Br)c2occc2c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TBXAS1 P24557 1/20 0.35
PKM P14618 1/20 0.35
CFD P00746 7/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
RECQL P46063 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
PRMT5 O14744 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672991 1.00 HPGD (0.40) HPGDKDM4EALDH1A1MAPTMEN1
Hexane SCHEMBL23217870 0.96 HPGD (0.38) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL30010940 0.89 TBXAS1 (0.38) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL23217611 0.89 TBXAS1 (0.38) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL23217814 0.86 CFD (0.36) HPGDKDM4EALDH1A1MAPTTBXAS1
SCHEMBL23217277 0.83 CFD (0.49) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL23217676 0.83 L3MBTL1 (0.35) HPGDKDM4EALDH1A1MAPTMEN1
SCHEMBL30010562 0.82 TBXAS1 (0.33) HPGDKDM4EALDH1A1MAPTNPSR1
SCHEMBL21438395 0.79 CFD (0.52) TBXAS1PKMCFDPRMT5
SCHEMBL30010728 0.79 CFD (0.52) TBXAS1PKMCFDPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB HPGD 336/4885KDM4E 4182/4885ALDH1A1 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.